Meeting
2020 ASCO Virtual Scientific Program
Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study.
Presenter
Michael B. Atkins, MD
Georgetown Lombardi Comprehensive Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02133742
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5080)
DOI
10.1200/JCO.2020.38.15_suppl.5080
Abstract #
5080
Poster Bd #
149
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
Speaker: Sun Young Rha, MD, PhD
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.
Speaker: Nizar M. Tannir, FACP, MD
Videos & Slides
2021 ASCO Annual Meeting
Efficacy outcomes of nivolumab + cabozantinib versus pembrolizumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).
Speaker: Bradley Alexander McGregor, MD
Videos & Slides
2021 ASCO Annual Meeting
Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.
Speaker: Hamid Emamekhoo, MD